NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains

BTIG Remains Positive on NeoGenomics (NEO) Following Q4 Results, Guidance; Affirms at 'Buy'

March 2, 2016 2:16 PM EST

BTIG reaffirms its Buy rating and $9 price target on NeoGenomics Inc. (Nasdaq: NEO) following Q4 results and outlook issued yesterday morning.

Analyst Sean Lavin noted that FY16 guidance was largely inline with prior expectations. Commentary around initial integration efforts was encouraging,... More

NeoGenomics (NEO) Tops Q4 EPS by 3c

March 1, 2016 7:06 AM EST

NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $27.3 million versus the consensus estimate of $26.46 million.

GUIDANCE:

NeoGenomics sees FY2016 EPS of $0.07-$0.12, versus the consensus of $0.07. NeoGenomics sees... More